ATX-101
DrugATX-101 single doses
Completed
NCT Number: NCT00835952
ATX-101 Abdominoplasty
Histopathological study of abdominal fat excised from subjects undergoing abdominoplasty
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
25 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
San Francisco, California, United States
Loading trial locations.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy subjects undergoing planned abdominoplasty
Exclusion criteria
- History of interventions in the abdominal area
Treatment and study plan
Primary outcomes
-
Adverse events, laboratory test results, physical examinations
Time frame: 1 - 28 days
Secondary outcomes
-
Histopathology
Time frame: 1 - 28 Days
Sponsors and collaborators
Lead sponsor
Kythera Biopharmaceuticals
Industry
Registry information
Official study title
Phase 1, Open-label Study of the Safety, Tolerability, and Histological Effect of Single Doses of ATX-101 (Sodium Deoxycholate for Injection) Administered in Abdominal Fat in Subjects Undergoing Abdominoplasty
Acronym: ATX-101-08-10
Important dates
- Study start
- 2008
- Primary completion
- 2009
- Study completion
- 2009
- First posted
- Feb 4, 2009
- Registry last updated
- Jan 27, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.